CTRI/2019/08/020638进行中（未招募）1 期
A Single-center, Randomized, Blinded, Placebo- and Active-controlled Crossover Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers
Zydus Discovery DMCC0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Provision of signed and dated written informed consent prior to any study-specific procedures being performed.
- •2)Willing and able to comply with the study procedures, restrictions, and requirements.
- •3)Body mass index of 19.0 to 25.0 kg/m2 (inclusive) with a body weight of 50 to 100 kg (inclusive).
- •4)Subjects must be non-smokers and must not drink alcohol (teetotal).
- •5)Subjects who, in the opinion of the Investigator, are healthy as determined by their pre-study medical history, physical examination, and 12-lead ECG, and clinical laboratory tests within the institutional normal range or judged as not clinically significant by the Investigator, including the following parameters: hematology, serum biochemistry, urinalysis, and serology.
- •6)Male subjects and female subjects of childbearing potential must practice highly effective contraception during the study and be willing and able to continue contraception for 90 days after their last administration of study treatment.
- •7)Systemic blood pressure with a systolic blood pressure of 100 to 140 mmHg and a diastolic blood pressure of 60 to 90 mmHg.
排除标准
- •1)History of cardiovascular disease (eg, hypertension, arrhythmia, heart failure, long QT syndrome, or other conditions/diseases causing prolongation of the QT/QTc interval), in the opinion of the Investigator.
- •2)A prolongation of the QT interval corrected for HR using Fridericiaâ??s correction (QTcF) interval (eg, repeated demonstration of a QTcF interval >450 msec) before study treatment administration.
- •3. Any clinically important abnormalities in the ECG at screening, check-in (Day -1), or predose on Day 1. This includes subjects with any of the following:
- •a. PR interval >210 msec;
- •b. QRS >110 msec; or
- •c. HR <45 beats per minute (bpm) or >100 bpm.
- •4)A QRS and/or T-wave value that the Investigator judges to be unfavorable for consistently accurate QT measurements (eg, indistinct QRS onset, low amplitude T-wave, inverted or terminally-inverted T-wave, merged T/U-waves, indistinct T-wave offset, or prominent U-wave that affects QT measurement).
- •5)History of additional risk factors for Torsades de Pointes or the presence of a family history of short QT syndrome, long QT syndrome, sudden unexplained death at a young age (<=40 years), drowning or sudden infant death syndrome in a first degree relative (ie, biological parent, sibling, or child).
- •6)Use of medications in the 90 days before Day -1 of Period 1 that are known to prolong the QT/QTc interval.
- •7)Has used prescription drugs and other substances (eg, dietary or herbal supplements such as St Johnâ??s Wort) known to be either significant enzyme inducers or enzyme inhibitors within 4 weeks of Day 1 of Period 1, or use of grapefruit or similar substances (Seville oranges or marmalade, grapefruit juice, grapefruit hybrids, pomelos, exotic citrus fruits or fruit juices) within 7 days of Day 1 of Period 1.
- •8)Has used prescription or over-the-counter medication, excluding routine vitamins but including megadose vitamin therapy (intake of 20 to 600 times the recommended daily dose), within 7 days of Day 1 of Period 1, unless agreed as not clinically relevant by the Investigator and Sponsor.
- •9)Any history of malignant disease, including solid tumors, hematologic malignancies, and including any carcinoma in situ.
- •10)Clinically significant allergies, as determined by the Investigator.
- •11)History of any clinically significant endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major diseases, as determined by the Investigator.
- •12) History of unexplained syncopal or hypotensive episodes.
- •13)A positive cotinine test and positive breath test at screening or check-in (Day -1) of Period 1.
- •14)Surgery within 12 months prior to check-in (Day -1) of Period 1 (other than minor cosmetic surgery and minor dental surgery).
- •15)Subjects who have recent illness (eg, fever >38°C) within 7 days of check-in (Day -1) of Period 1.
- •16)Clinically significant abnormal hematology and serum biochemistry values, as determined by the Investigator or any of the following values at screening or check-in (Day -1) of Period 1:
- •a. Alanine aminotransferase, aspartate aminotransferase, or creatinine above their reference range.
- •b. Hemoglobin or platelets below their reference range.
研究者
相似试验
已完成
2 期
Covid Investigator Initiate Study on ProbenecidCTRI/2022/07/043726Dr Neelam Pandey75
进行中（未招募）
1 期
A study to investigate safety, tolerability, and pharmacokinetics of AZD7503 in healthy Japanese participants.nonalcoholic fatty liver diseaseJPRN-jRCT2071230075Ageishi Yuji12
招募中
不适用
Intervention Study to evaluate Body Fat Reduction Efficacy and Safety of 'BN-202M' in Overweight SubjectsKCT0007268Hecto Healthcare100
进行中（未招募）
不适用
Study of BOTOX® in the treatment of Osteoarthritis Knee PaiTreatment of Osteoarthritis Knee PainMedDRA version: 14.0Level: LLTClassification code 10031165Term: Osteoarthritis kneeSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-002768-25-DKAllergan Limited
进行中（未招募）
Unknown
A clinical trial to study the safety and immunogenecity (the ability of a molecule or substance to provoke an immune response”) of Varicella zoster virus vaccine in healthy male and female adultsVaricella-zoster VirusInfection - Studies of infection and infectious agentsACTRN12623000947606Bestudy Australia Pty Ltd100